Loading
Socazolimab is Lee's Pharmaceutical's PD-L1 antibody, in phase 3 trials in China for extensive-stage small cell lung cancer and recurrent cervical cancer.
Socazolimab (ZKAB001), licensed by Lee's Pharmaceutical from Sorrento, is a fully human PD-L1 antibody. Its phase 3 programme in China includes first-line extensive-stage small cell lung cancer with chemotherapy and recurrent or metastatic cervical cancer; earlier trials included osteosarcoma. OnCo records its Chinese regulatory status only where a source states it.
Binds PD-L1 on tumour and immune cells so it cannot engage PD-1 on T cells. Connects to PD-L1.
1.Socazolimab binds PD-L1.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Socazolimab" OR ABSTRACT:"Socazolimab" OR TITLE:"ZKAB001" OR ABSTRACT:"ZKAB001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Socazolimab, not a curated reading list.
Shares Small-cell lung cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares PD-L1 and the tag pipeline.
Shares Small-cell lung cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares PD-L1 and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.